Equity Profile

ARWR

Arrowhead Pharmaceuticals, Inc.

Health CareBiotechnology$10.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ3-2026After Close5:00 PM EDT

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases. With a market cap of $10 billion, it operates in the health care sector, emphasizing gene silencing technologies that could revolutionize treatment options for various conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q2-2026, Arrowhead reported an EPS of -$0.93, which was better than the expected -$1.18, leading to a slight decline in stock price the following day. The company continues to navigate challenges in revenue generation while focusing on its pipeline.

Management Promises & Guidance

Commitment to advancing clinical trials for its lead drug candidates.
Focus on cost management to improve future profitability.
Plans to provide more transparency on revenue expectations in future calls.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Arrowhead's upcoming earnings, given the recent EPS surprise. However, there are concerns about the sustainability of revenue growth and ongoing clinical developments.

Bull Case

If Arrowhead can demonstrate significant progress in its clinical trials and improve its revenue outlook, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations for clinical advancements or shows continued losses, it could further dampen investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will be provided on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly influence future revenue potential.

How does management plan to address the ongoing losses and improve revenue generation?

Understanding management's strategy for cost management and revenue growth is crucial for assessing the company's financial health moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arrowhead's clinical advancements to translate into revenue sooner than expected, particularly given recent positive trial results.

Supporting Evidence

The options market is pricing a 21.53% move, indicating greater uncertainty than historical averages suggest.

Insider selling could indicate a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will heavily depend on Arrowhead's ability to balance its clinical advancements with financial performance.

Bull Confirmed If

Demonstrating a clear path to profitability with a significant reduction in losses or a positive EPS.

Bear Confirmed If

Continued losses without a clear revenue growth strategy or clinical trial setbacks.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations and raises guidance, history suggests a potential stock increase of around +2.86%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of approximately -0.17%, reinforcing bearish sentiment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for clinical trial results.
2Details on cost management strategies and their expected impact on future profitability.
3Any new partnerships or collaborations that could enhance revenue.
4Management's outlook on market demand for their products.
5Responses to analyst questions regarding insider selling activity.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

Management Promises & Guidance

Commitment to advancing clinical trials for its lead drug candidates.
Focus on cost management to improve future profitability.
Plans to provide more transparency on revenue expectations in future calls.

Expectations

Wall Street Expectations

Bull Case

If Arrowhead can demonstrate significant progress in its clinical trials and improve its revenue outlook, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company fails to meet expectations for clinical advancements or shows continued losses, it could further dampen investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will be provided on the progress of ongoing clinical trials?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly influence future revenue potential.

How does management plan to address the ongoing losses and improve revenue generation?

Understanding management's strategy for cost management and revenue growth is crucial for assessing the company's financial health moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arrowhead's clinical advancements to translate into revenue sooner than expected, particularly given recent positive trial results.

Supporting Evidence

The options market is pricing a 21.53% move, indicating greater uncertainty than historical averages suggest.

Insider selling could indicate a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will heavily depend on Arrowhead's ability to balance its clinical advancements with financial performance.

Bull Confirmed If

Demonstrating a clear path to profitability with a significant reduction in losses or a positive EPS.

Bear Confirmed If

Continued losses without a clear revenue growth strategy or clinical trial setbacks.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations and raises guidance, history suggests a potential stock increase of around +2.86%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react moderately, reflecting uncertainty in future growth.

Miss

A miss on earnings could lead to a decline of approximately -0.17%, reinforcing bearish sentiment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for clinical trial results.
2Details on cost management strategies and their expected impact on future profitability.
3Any new partnerships or collaborations that could enhance revenue.
4Management's outlook on market demand for their products.
5Responses to analyst questions regarding insider selling activity.